RPRX
NASDAQRoyalty Pharma plc
Price$60.97+0.97 (+1.62%)
01:30 PM07:45 PM
News · 26 weeks61+100%
2026-04-192026-10-11
Mix2690d
- Insider10(38%)
- M&A6(23%)
- SEC Filings4(15%)
- Other3(12%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- PRRoyalty Pharma declares fourth quarter 2026 dividendNEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical com
- PRRoyalty Pharma to announce third quarter 2026 financial results on November 4, 2026NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma plc Founded in 1996, Royalty Pha
- INSIDERSEC Form 4 filed by Royalty Pharma plc4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDERDirector Bassler Bonnie L was granted 642 units of Class A Ordinary Shares, increasing direct ownership by 0.81% to 79,823 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall sold $238,813 worth of Class A Ordinary Shares (4,126 units at $57.88) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 4,126 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Chairman, Partnering Hite Christopher sold $5,853,095 worth of Class A Ordinary Shares (100,000 units at $58.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration ProgramNEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies. The donation marks a new phase for TAP, with Royalty Pharma serving as the first and largest corporate donor under an updated model that invites direct donations to the program. TAP donations are deployed as venture capital investments in early-stage biotech
- PRRoyalty Pharma to present at upcoming investor conferencesNEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDTBofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST The webcast will be accessible from Royalty Pharma’s "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and
- PRRoyalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenNEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical con
- INSIDEREVP & Chairman, Partnering Hite Christopher sold $5,997,250 worth of Class A Ordinary Shares (100,000 units at $59.97) as part of a pre-agreed trading plan and gifted 16,800 units of Class A Ordinary Shares, decreasing direct ownership by 42% to 23,200 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Royalty Pharma plcSCHEDULE 13D/A - Royalty Pharma plc (0001802768) (Subject)
- INSIDEREVP & CFO Coyne Terrance P. sold $645,551 worth of Class A Ordinary Shares (11,002 units at $58.68) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 13F-NT filed by Royalty Pharma plc13F-NT - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form 144 filed by Royalty Pharma plc144 - Royalty Pharma plc (0001802768) (Subject)
- SECSEC Form 144 filed by Royalty Pharma plc144 - Royalty Pharma plc (0001802768) (Subject)
- PRRoyalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 millionNEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. "We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "This transaction underscores Royalty Pharma’s role as a long-term
- PRZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideCompany announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma’s key strategic priorities. Copenhagen, Denmark, August 12, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has entered into a ro
- INSIDERCEO, Chairman of the Board Legorreta Pablo G. was granted 65,216 units of Class A Ordinary Shares, increasing direct ownership by 5% to 1,307,820 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & CFO Coyne Terrance P. was granted 11,002 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Chairman, Partnering Hite Christopher was granted 11,002 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall was granted 8,252 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 10-Q filed by Royalty Pharma plc10-Q - Royalty Pharma plc (0001802768) (Filer)
- SECRoyalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Royalty Pharma plc (0001802768) (Filer)
- PRRoyalty Pharma reports second quarter 2026 resultsPortfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14%Net cash provided by operating activities of $728 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. "Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%," said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. "Our transaction pipeline remains exciting and we continued to bolster our de
- PRRoyalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesNEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center. "We are delighted to welcome Greg to Royalty Pharma," said Pablo Legorreta, Chief Executive Officer and Chairman
RPRX FAQ
7 questionsWhat does Royalty Pharma plc do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that...Where does RPRX stock trade?
Royalty Pharma plc (RPRX) is listed on NASDAQ.What sector and industry is RPRX in?
Royalty Pharma plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Royalty Pharma plc go public?
Royalty Pharma plc (RPRX) completed its IPO in 2020.What are analysts saying about RPRX?
Royalty Pharma plc has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $4900.00 price target on 2026-01-30. Recent price targets range from $2800.00 to $4900.00.What companies are similar to RPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RPRX side-by-side with any of them on Quantisnow.How can I track RPRX on Quantisnow?
Quantisnow aggregates Royalty Pharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RPRX to receive live email and push alerts on every new disclosure.